Saturday 7 November 2026 Export CVM’s income statement to Excel — free account

Cel-Sci Corporation

CVM Healthcare Biotechnology

EPS: +65.4%
Free cash flow: −2.33%
Total debt: −39.7%

Quarter to June 2026, against a year earlier

1.45 0.08 +5.84%

Follow CVM

Alert me

Market cap: $24.1M
P/E: 0.0×
Fwd P/E: −12.2×
Dividend yield: —
F-score: 4/9
Altman Z: −1.63
Beneish M: −2.35
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.87

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	1	1	—	—	—	2	—	—	1	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 24.09

Revenue ttm 0.56

Net income ttm (22.70)

Free cash flow ttm (16.75)

Net debt Q (2.74)

Valuation

P/E 0.00

Forward P/E (12.20)

Price / sales 31.44

Forward P/S Powerpack

Price / FCF 0.00

Price / book 1.60

Financial health

Current ratio Q 1.48

Debt / equity Q 0.35

Interest coverage Q (50.43)

Growth

Revenue growth Q −62.66%

Operating income growth Q −1.25%

EPS, this year −16.20%

EPS, next year A +22.39%

Revenue, next year A −100.00%

EPS, past 5 yrs —

EPS, next 5 yrs A +25.29%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 4.55%

10-year low 10-year high

P/B against its own 10 years 4.91%

10-year low 10-year high

EV/Sales against its own 10 years 3.59%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	5	11	7
Receivables	—	—	—	—
Inventory	2	1	0	0
Other	0	0	0	0
	7	6	12	8

	2023	2024	2025	Q'26
Payables	2	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	6	5	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	21.44%	16.18%	25.14%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(4.15%)	(20.84%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY24 Estimate −3.90 Actual −4.20

−5.98 −5.39 −4.80 −4.22 −3.63

Q3 FY23 Miss −0.60

Q4 FY23 Met 0.00

Q2 FY24 Met 0.00

Q3 FY24 Miss −0.30

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY23	−5.11	−5.71	Miss by 0.60
Q4 FY23	−4.80	−4.80	Met by 0.00
Q2 FY24	−4.20	−4.20	Met by 0.00
Q3 FY24	−3.90	−4.20	Miss by 0.30

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.68)	(0.67)	(0.47)	—	—
’25	(3.30)	(2.40)	(1.36)	(0.86)	(6.27)
’24	(4.20)	(4.20)	(4.20)	(2.96)	(15.31)
’23	(5.41)	(5.71)	(5.71)	(4.80)	(21.92)
’22	(6.01)	(6.91)	(6.91)	(6.31)	(26.13)
’21	(6.31)	(8.41)	(7.51)	(5.71)	(27.93)
’20	(4.80)	(7.51)	(8.11)	(4.20)	(24.62)

Fiscal quarters ending in the months shown.

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	—	—	—	—	—
’20	0	0	0	0	1
’19	0	0	0	0	0
’18	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(4)	(4)	(4)	—	—
’25	(4)	(4)	(4)	(5)	(17)
’24	(5)	(5)	(5)	(5)	(19)
’23	(5)	(7)	(6)	(5)	(23)
’22	(5)	(3)	(6)	(5)	(18)
’21	(4)	(5)	(5)	(5)	(19)
’20	(4)	(4)	(4)	(4)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(4)	(4)	(4)	—	—
’25	(4)	(4)	(4)	(5)	(17)
’24	(5)	(5)	(5)	(5)	(19)
’23	(5)	(8)	(6)	(5)	(23)
’22	(5)	(3)	(6)	(5)	(19)
’21	(7)	(8)	(7)	(5)	(28)
’20	(4)	(5)	(5)	(5)	(18)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	—	0	0	1	—	—	—	—	—	1		+18.3%	—	6	—	—
	Gross margin, %	100.00	0.00	100.00	100.00	100.00	0.00	0.00	0.00	—	—	0.00		(100.0) pt	Powerpack Cel-Sci Corporation’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(12)	(14)	(32)	(22)	(30)	(36)	(37)	(32)	(27)	(25)	(23)		+9.2%
	EBT margin, %	(4,038.06)	0.00	(6,680.07)	(4,782.76)	(5,415.30)	0.00	0.00	0.00	0.00	0.00	0.00		+4,038.1 pt
	Net income	(12)	(14)	(32)	(22)	(30)	(36)	(37)	(32)	(27)	(25)	(23)		+9.2%
Per share, $
Per share, $	Revenue	1.76	0.00	0.84	0.45	0.46	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Earnings	(67.57)	(54.95)	(56.16)	(21.32)	(24.62)	(27.03)	(26.13)	(21.92)	(15.31)	(6.27)	(2.68)		(23.2%)
	Cash flow	(142.48)	(52.48)	(23.64)	(15.72)	(12.48)	(13.88)	(12.69)	(15.43)	(10.44)	(4.22)	(1.38)		(32.4%)
	Capex	(0.21)	(0.06)	(0.10)	(0.32)	(2.20)	(6.68)	(0.46)	(0.25)	(0.06)	(0.01)	0.00		(29.2%)
	Free cash flow	(142.70)	(52.55)	(23.75)	(16.05)	(14.68)	(20.55)	(13.15)	(15.68)	(10.50)	(4.23)	(1.38)		(32.4%)
	Book value	(4.19)	(12.70)	0.00	4.95	16.12	41.75	22.38	8.92	7.14	3.93	0.90		n/m
	Shares, m	0	0	1	1	1	1	1	1	2	4	8		+43.0%
Valuation, ×
Valuation, ×	P/E	0.00	—	0.00	0.00	0.00	—	—	—	—	—	0.00		0.0
	P/S	132.11	—	151.86	601.79	838.14	—	—	—	—	—	31.44		431.0
	P/B	0.00	—	80,420.89	54.24	23.74	—	—	—	—	—	1.60		20,124.7
	EV/Sales	171.39	—	160.62	615.12	833.33	—	—	—	—	—	27.64		445.1
	EV/FCF	(2.11)	—	(5.69)	(17.09)	(25.91)	—	—	—	—	—	(0.92)		(12.7)
Cash, $m
Cash, $m	Operating cash flow	(23)	(14)	(13)	(16)	(15)	(19)	(18)	(23)	(19)	(17)	(17)		(3.3%)
	Capex	0	0	0	0	(3)	(9)	(1)	0	0	0	0		+1.2%
	Free cash flow	(23)	(14)	(13)	(17)	(18)	(28)	(19)	(23)	(19)	(17)	(17)		(3.3%)
Balance, $m
Balance, $m	Working capital	1	(7)	2	7	13	41	21	1	1	6	2		+18.1%
	Net debt	10	11	3	5	(4)	(29)	(11)	6	3	(5)	(3)		n/m
	Shareholders’ equity	(1)	(3)	0	5	20	57	32	13	13	16	11		n/m
Returns, %
Returns, %	ROA	(43.09)	(60.35)	(121.31)	(77.38)	(88.84)	(63.08)	(59.54)	(79.86)	(95.90)	(92.16)	(108.91)		(49.1) pt
	ROIC	(157.00)	(178.26)	(341.36)	(123.78)	(113.43)	(82.04)	(106.25)	(103.44)	(102.38)	(145.08)	(169.59)		+11.9 pt
	ROE	423.14	718.45	1,909.51	(862.17)	(243.58)	(96.28)	(84.85)	(142.65)	(211.49)	(176.32)	(252.53)		(599.5) pt
People
People	Employees	—	—	—	—	—	—	—	—	—	—	—		—
	Revenue/emp, $m	0.00	—	0.00	0.00	0.00	—	—	—	—	—	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Sep 2020 · latest quarter Sep 2020 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BYSI BeyondSpring Inc.	$26.0M	— (loss-making)	— (loss-making)	+87.78% (above 0%: growing)	n/m	+35.78% (above 0%: growing)	100.00%	0.00%	Compare
ABVC ABVC BioPharma, Inc.	$25.9M	— (loss-making)	— (loss-making)	+66,233.33% (above 0%: growing)	n/m	+72.66% (above 0%: growing)	100.00%	0.00%	Compare
RNAZ TransCode Therapeutics Inc.	$25.6M	— (loss-making)	—	—	n/m	−28.79% (below 0%: shrinking)	0.00%	0.00%	Compare
AARD Aardvark Therapeutics, Inc.	$24.3M	— (loss-making)	—	—	n/m	−77.14% (below 0%: shrinking)	—	0.00%	Compare
CVM Cel-Sci Corporation	$24.1M	— (loss-making)	— (loss-making)	−62.66% (below 0%: shrinking)	n/m	−2.33% (below 0%: shrinking)	0.00%	0.00%
CELU Celularity, Inc.	$23.5M	— (loss-making)	— (loss-making)	−5.30% (below 0%: shrinking)	n/m	−10.91% (below 0%: shrinking)	56.79%	(78.00%)	Compare
NXTC NextCure, Inc.	$23.4M	— (loss-making)	— (loss-making)	+1,549.08% (above 0%: growing)	n/m	+57.23% (above 0%: growing)	0.00%	0.00%	Compare
EVAX Evaxion A/S - Sponsored ADR	$23.0M	— (loss-making)	— (loss-making)	+14,590.20% (above 0%: growing)	n/m	−56.70% (below 0%: shrinking)	100.00%	0.00%	Compare
IGC IGC Pharma, Inc.	$22.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−45.33% (below 0%: shrinking)	18.60%	(588.72%)	Compare
Median of peers	$23.9M	—	—	+818.43%	—	−19.85%	56.79%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 2 July 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	919.85k	617.86k	9,920.00
2024	1.07m	911.92k	9,650.00
2023	1.03m	660.40k	11,370.00

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Cel-Sci Corporation (CVM) Latest News

29 Oct

Impact 4 · 1:42 PM · Proactive

CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis

26 Oct

Impact 4 · 8:00 AM · Business Wire

CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival

17 Aug

Impact 3 · 8:30 AM earnings

CEL-SCI Reports Fiscal Third Quarter 2026 Results

4 Aug

Impact 4 · 8:00 AM

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study

30 Jul

Impact 4 · 8:31 AM

Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

13 Jul

Impact 4 · 8:00 AM

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

24 Jun

Impact 3 · 8:00 AM · Business Wire

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

16 Jun

Impact 4 · 8:00 AM

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

Impact 3 · 4:01 PM

CEL-SCI Announces Closing of Offering

15 Jun

Impact 3 · 7:12 AM · Stocktwits

CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month

14 Jun

Impact 3 · 7:03 PM

CEL-SCI Corporation Announces Pricing of Offering

12 Jun

Impact 3 · 8:00 AM

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

13 May

Impact 4 · 3:00 PM · Business Wire

CEL-SCI Announces Closing of Public Offering

11 May

Impact 4 · 8:11 PM · Business Wire

CEL-SCI Corporation Announces Pricing of Public Offering

Impact 4 · 8:00 AM · Business Wire

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

18 Feb

Impact 3 · 9:00 AM · Business Wire

CEL-SCI Reports Fiscal First Quarter 2026 Results

17 Feb

Impact 3 · 5:14 PM · Associated Press Finance

Cel-Sci: Fiscal Q1 Earnings Snapshot

29 Dec

Impact 4 · 9:00 AM · Business Wire

CEL-SCI Reports Fiscal 2025 Results

10 Oct

Impact 3 · 8:00 AM · Newsfile

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

29 Aug

Impact 3 · 12:52 PM

CEL-SCI Announces Closing of $10 Million Public Offering

27 Aug

Impact 3 · 10:35 PM

CEL-SCI Announces Pricing of $10 Million Public Offering

Impact 3 · 5:25 PM · Business Wire

CEL-SCI Announces Proposed Public Offering

14 Aug

Impact 3 · 10:45 AM

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

Impact 3 · 9:37 AM · Associated Press Finance

Cel-Sci: Fiscal Q3 Earnings Snapshot

13 Aug

Impact 4 · 9:15 AM · Business Wire

CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

14 Jul

Impact 3 · 4:05 PM

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

11 Jul

Impact 4 · 9:15 AM

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Impact 3 · 12:16 PM · Business Wire

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

18 Jun

Impact 4 · 9:00 AM · Business Wire

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

23 May

Impact 4 · 4:05 PM · Business Wire

CEL-SCI Announces Closing of Public Offering

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to September

Cel-Sci Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 2 July 2026

Chief executive’s pay

Cel-Sci Corporation (CVM) Latest News

29 Oct

26 Oct

17 Aug

4 Aug

30 Jul

13 Jul

24 Jun

16 Jun

15 Jun

14 Jun

12 Jun

13 May

11 May

18 Feb

17 Feb

29 Dec

10 Oct

29 Aug

27 Aug

14 Aug

13 Aug

14 Jul

11 Jul

18 Jun

23 May

Stockrow Weekly